HilleVax, Inc. (NASDAQ:HLVX) Short Interest Update

HilleVax, Inc. (NASDAQ:HLVX) was the target of a significant drop in short interest during the month of September. As of September 15th, there was short interest totalling 1,860,000 shares, a drop of 5.6% from the August 31st total of 1,970,000 shares. Currently, 10.2% of the company’s shares are sold short. Based on an average daily volume of 1,110,000 shares, the short-interest ratio is presently 1.7 days.

Institutional Investors Weigh In On HilleVax

Institutional investors have recently added to or reduced their stakes in the company. Swiss National Bank lifted its stake in HilleVax by 22.4% in the 4th quarter. Swiss National Bank now owns 38,200 shares of the company’s stock worth $613,000 after acquiring an additional 7,000 shares in the last quarter. Catalys Pacific LLC bought a new stake in HilleVax during the fourth quarter valued at about $21,009,000. EntryPoint Capital LLC acquired a new position in shares of HilleVax during the first quarter worth approximately $80,000. Tidal Investments LLC bought a new stake in shares of HilleVax in the 1st quarter worth approximately $207,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of HilleVax by 35.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 93,865 shares of the company’s stock worth $1,357,000 after buying an additional 24,410 shares in the last quarter. 86.42% of the stock is currently owned by institutional investors and hedge funds.

HilleVax Stock Up 1.1 %

Shares of NASDAQ:HLVX opened at $1.78 on Wednesday. The company has a market cap of $88.50 million, a price-to-earnings ratio of -0.54 and a beta of 0.81. HilleVax has a fifty-two week low of $1.55 and a fifty-two week high of $20.22. The firm’s 50-day simple moving average is $1.79 and its 200-day simple moving average is $8.72.

HilleVax (NASDAQ:HLVX) last released its earnings results on Thursday, August 8th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.10). On average, research analysts forecast that HilleVax will post -2.47 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on HLVX shares. Leerink Partners cut HilleVax from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $28.00 to $2.00 in a report on Tuesday, July 9th. HC Wainwright reiterated a “neutral” rating and set a $2.00 price objective on shares of HilleVax in a research note on Monday, August 12th. Leerink Partnrs lowered HilleVax from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 9th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $5.00 price objective (down previously from $24.00) on shares of HilleVax in a research note on Monday, July 8th. Finally, Guggenheim lowered HilleVax from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Six analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, HilleVax presently has a consensus rating of “Hold” and an average price target of $9.20.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.